Currently, there are 1.00B common shares owned by the public and among those 1.00B shares have been available to trade.
The company’s stock has a 5-day price change of 0.32% and -4.58% over the past three months. EXC shares are trading 0.74% year to date (YTD), with the 12-month market performance up to 4.72% higher. It has a 12-month low price of $33.35 and touched a high of $41.19 over the same period. EXC has an average intraday trading volume of 6.39 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.47%, -0.16%, and 0.40% respectively.
Institutional ownership of Exelon Corp (NASDAQ: EXC) shares accounts for 83.74% of the company’s 1.00B shares outstanding.
It has a market capitalization of $38.10B and a beta (3y monthly) value of 0.54. The stock’s trailing 12-month PE ratio is 15.63, while the earnings-per-share (ttm) stands at $2.43. The company has a PEG of 2.74 and a Quick Ratio of 0.97 with the debt-to-equity ratio at 1.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.44% over the week and 1.77% over the month.
Analysts forecast that Exelon Corp (EXC) will achieve an EPS of 0.6 for the current quarter, 0.7 for the next quarter and 2.63 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.55 while analysts give the company a high EPS estimate of 0.55. Comparatively, EPS for the current quarter was 0.6 a year ago. Earnings per share for the fiscal year are expected to increase by 3.04%, and 7.26% over the next financial year. EPS should grow at an annualized rate of 5.70% over the next five years, compared to 2.40% over the past 5-year period.
Looking at the support for the EXC, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on September 20, 2024, with the firm’s price target at $46. Mizuho coverage for the Exelon Corp (EXC) stock in a research note released on January 10, 2024 offered a Buy rating with a price target of $39. Seaport Research Partners was of a view on January 08, 2024 that the stock is Neutral, while UBS gave the stock Neutral rating on January 02, 2024, issuing a price target of $47- $37. Morgan Stanley on their part issued Equal-Weight rating on December 18, 2023.
